Stocks and Investing Stocks and Investing
Tue, May 14, 2024
Mon, May 13, 2024

Michael Ulz Maintained (ARWR) at Hold with Decreased Target to $27 on, May 13th, 2024


Published on 2024-10-28 11:19:30 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Decreased Target from $36 to $27 on, May 13th, 2024.

Michael has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024


These are the ratings of the 2 analyists that currently disagree with Michael


  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy and Held Target at $60 on, Friday, May 10th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024

Contributing Sources